Telesis Bio logo

Telesis BioNASDAQ: TBIO

Profile

Sector:

Healthcare

Country:

United States

IPO:

18 June 2021

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$70.52 M
-99%vs. 3y high
39%vs. sector
-vs. 3y high
-vs. sector
-100%vs. 3y high
7%vs. sector
-99%vs. 3y high
56%vs. sector

Price

regular market | Fri, 15 Nov 2024 14:30:00 GMT
$0.93+$0.01(+1.41%)

Dividend

No data over the past 3 years
$1.55 M$930.00 K
$1.55 M-$12.59 M

Analysts recommendations

Institutional Ownership

TBIO Latest News

Why Is Telesis Bio (TBIO) Stock Up 29% Today?
InvestorPlace23 February 2024 Sentiment: POSITIVE

Telesis Bio (NASDAQ: TBIO ) stock is on the rise Friday as the synthetic biology company's shares experienced heavy trading this morning. Shares of TBIO stock are off to a strong start on Friday with some 7.4 million shares changing hands as of this writing.

Telesis Bio to Present at Jefferies Healthcare Conference 2023
GlobeNewsWire08 June 2023 Sentiment: POSITIVE

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of Telesis Bio will present today at the 2023 Jefferies Healthcare Conference, Thursday, June 8, 2023, at 10:00 am Eastern time / 7:00 am Pacific Time.

Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023
GlobeNewsWire06 June 2023 Sentiment: POSITIVE

Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery

Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research11 May 2023 Sentiment: NEUTRAL

Telesis Bio (TBIO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.45 per share a year ago.

Telesis Bio, Inc. (TBIO) Q4 2022 Earnings Call Transcript
Seeking Alpha25 March 2023 Sentiment: POSITIVE

Telesis Bio, Inc. (NASDAQ:TBIO ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Jen Carroll - VP, IR Todd Nelson - President, CEO & Director Eric Esser - COO Conference Call Participants Brandon Couillard - Jefferies Harrison Schrage - KeyBanc Capital Markets Poon Mah - TD Cowen Operator Good day, and thank you for standing by, and welcome to the Q4 2022 Telesis Bio Earnings Conference Call. [Operator Instructions].

What type of business is Telesis Bio?

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

What sector is Telesis Bio in?

Telesis Bio is in the Healthcare sector

What industry is Telesis Bio in?

Telesis Bio is in the Medical Devices industry

What country is Telesis Bio from?

Telesis Bio is headquartered in United States

When did Telesis Bio go public?

Telesis Bio initial public offering (IPO) was on 18 June 2021

What is Telesis Bio website?

https://telesisbio.com

Is Telesis Bio in the S&P 500?

No, Telesis Bio is not included in the S&P 500 index

Is Telesis Bio in the NASDAQ 100?

No, Telesis Bio is not included in the NASDAQ 100 index

Is Telesis Bio in the Dow Jones?

No, Telesis Bio is not included in the Dow Jones index

When was Telesis Bio the previous earnings report?

No data

When does Telesis Bio earnings report?

Next earnings report date is not announced yet